Absci

Absci is a Vancouver, Washington-based generative AI drug creation company (NASDAQ: ABSI) using AI and synthetic biology to design de novo antibodies in silico against specified epitopes. Its Integrated Drug Creation platform couples generative AI models — including the Origin-1 antibody foundation model — with a 77,000+ sq ft wet lab running proprietary SoluPro and ACE Assay technologies, screening millions of antibody sequence variants per cycle. The data flywheel between in silico design and high-throughput wet lab validation completes in as little as six weeks and can advance from target identification to development candidate in roughly 14 months. Absci's internal pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease now in Phase 1; ABS-201, a novel anti-PRLR antibody for androgenetic alopecia in the Phase 1/2a HEADLINE trial; and ABS-301, a first-in-class AI-discovered oncology antibody. Strategic partnerships span AstraZeneca, Merck, Almirall, Twist Bioscience, NVIDIA, Owkin, Caltech, and the Gates Foundation. Absci's commercial model is therapeutic development (internal pipeline plus partnered programs and royalties); there is no public developer API, SDK, or open-source release of the Origin-1 model or its drug creation platform.

Absci is profiled on the APIs.io network. Tagged areas include Drug Discovery, Biotechnology, Generative AI, Antibody Design, and De Novo Antibody Generation.

Absci’s developer surface includes YouTube channel and 14 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

Drug DiscoveryBiotechnologyGenerative AIAntibody DesignDe Novo Antibody GenerationAI for BiologySynthetic BiologyFoundation ModelsOrigin-1Integrated Drug CreationTherapeuticsNASDAQ

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 6.8/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/absci: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Learn 1

Tutorials, courses, talks, and written guidance

YouTube

YouTube

Operate 2

Status, limits, changes, and where to get help

PressReleases

PressReleases

Contact

Contact

Company 7

The organization behind the API

Website

Partnerships

About

Investors

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 4

Properties that don't map to a standard resource type

Technology

Science

Pipeline

SECFilings

Source (apis.yml)

aid: absci
name: Absci
description: 'Absci is a Vancouver, Washington-based generative AI drug creation company (NASDAQ: ABSI) using AI and synthetic
  biology to design de novo antibodies in silico against specified epitopes. Its Integrated Drug Creation platform couples
  generative AI models — including the Origin-1 antibody foundation model — with a 77,000+ sq ft wet lab running proprietary
  SoluPro and ACE Assay technologies, screening millions of antibody sequence variants per cycle. The data flywheel between
  in silico design and high-throughput wet lab validation completes in as little as six weeks and can advance from target
  identification to development candidate in roughly 14 months. Absci''s internal pipeline includes ABS-101, an anti-TL1A
  antibody for inflammatory bowel disease now in Phase 1; ABS-201, a novel anti-PRLR antibody for androgenetic alopecia in
  the Phase 1/2a HEADLINE trial; and ABS-301, a first-in-class AI-discovered oncology antibody. Strategic partnerships span
  AstraZeneca, Merck, Almirall, Twist Bioscience, NVIDIA, Owkin, Caltech, and the Gates Foundation. Absci''s commercial model
  is therapeutic development (internal pipeline plus partnered programs and royalties); there is no public developer API,
  SDK, or open-source release of the Origin-1 model or its drug creation platform.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/absci.png
tags:
- Drug Discovery
- Biotechnology
- Generative AI
- Antibody Design
- De Novo Antibody Generation
- AI for Biology
- Synthetic Biology
- Foundation Models
- Origin-1
- Integrated Drug Creation
- Therapeutics
- NASDAQ
url: https://raw.githubusercontent.com/api-evangelist/absci/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/absci-domain-security.yml
- type: Website
  url: https://www.absci.com
- type: Technology
  url: https://www.absci.com/technology/
- type: Science
  url: https://www.absci.com/science/
- type: Pipeline
  url: https://www.absci.com/pipeline/
- type: Partnerships
  url: https://www.absci.com/partnerships/
- type: About
  url: https://www.absci.com/about/
- type: Investors
  url: https://investors.absci.com
- type: PressReleases
  url: https://investors.absci.com/news-releases
- type: SECFilings
  url: https://investors.absci.com/financial-information/sec-filings
- type: Careers
  url: https://www.absci.com/careers/
- type: Contact
  url: https://www.absci.com/contact/
- type: LinkedIn
  url: https://www.linkedin.com/company/absci
- type: Twitter
  url: https://twitter.com/Absci_AI
- type: YouTube
  url: https://www.youtube.com/@absci_AI
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com